ArticleMikrochimica acta2024
Development of a colorimetric/fluorescence dual-mode immunoassay for aflatoxin B1 based on streptavidin-induced gold nanoparticle aggregation.
Article in Mikrochimica acta, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ultrasensitive Lateral Flow Immunoassay for Aflatoxin B1 Detection via Magnetic Enrichment-Catalytic Signal Amplification.Foods (Basel, Switzerland) · 2026Article
- Nanostructure-Engineered Optical and Electrochemical Biosensing Toward Food Safety Assurance.Foods (Basel, Switzerland) · 2025Review
- Bio-nanoparticles sensor couple with smartphone digital image colorimetry and dispersive liquid-liquid microextraction for aflatoxin B1 detection.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A dual-mode immunoassay method was developed for colorimetric and fluorescence detection of aflatoxin B1 (AFB1) based on streptavidin-induced gold nanoparticle aggregation (AuNP@SA). AuNP-modified streptavidin-biotin labeling AFB1 complete antigen aggregations (AuNP@SA@Bio-BSA-AFB1) were synthesized as the competitive binding and dual-mode probe. AuNP@SA@Bio-BSA-AFB1 aggregations possessed high colorimetric and fluorescence quenching intensities. AFB1 antibodies modified immunomagnetic microspheres were used as the capture probe. The competitive binding between AFB1 and AuNP@SA@Bio-BSA-AFB1 leads to changes in color and fluorescence intensity. The detection limit of the colorimetric method is 6.95 ng·mL
Indexed as
Identifiers
39643724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.